Puma Biotech (PBYI) Tops Q2 EPS, Revenues Miss

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.32, $0.34 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $51.6 million.

Net cash used in operating activities for the second quarter of 2021 was $0.1 million, compared to net cash provided by operating activities of $16.2 million in the second quarter of 2020. Net cash provided by operating activities for the first six months of 2021 was $15.6 million, compared to net cash provided by operating activities of $4.7 million for the first six months of 2020. At June 30, 2021, Puma had cash, cash equivalents and marketable securities of $108.9 million, compared to $93.4 million at December 31, 2020.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Endexx Corporation (EDXC) Reports Q1 Loss of $0.01
• Community West Bancshares (CWBC) Tops Q1 EPS by 7c